Quinoline derivatives as inhibitors of heat shock factor 1 pathway activity

A compound of formula Ia shown below, or a pharmaceutically acceptable salt thereof:

• wherein:
• C1 is CRa1;
• C2 is CRa2;
• Ra1 and Ra2 are each independently selected from hydrogen, fluoro, chloro, cyano, (1-2C)alkyl, (1-2C)alkoxy or (1-2C)haloalkyl;
• C3 is O or CH;
• C4 is O or CH;
• a is 0, 1 or 2;
• Rb is fluoro or (1-2C)alkyl;
• subject to the proviso that:
• (i) one or two of C3 or C4 are oxygen;
• and
• (i) when C3 and C4 are both oxygen then a is 1 or 2;
• R4 is selected from hydrogen, fluoro, chloro, bromo, iodo, CF3, OCF3, cyano, NO2, (1-4C)alkyl, (1-4C)alkoxy, or a group of the formula:
• W—X—Y—Z
• wherein:
• W is absent or (1-3C)alkylene;
• X is —O— or —N(R40)—, wherein R40 is selected from hydrogen or (1-2C)alkyl;
• Y is absent or a (1-3C)alkylene;
• Z is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl or a 4 to 10-membered monocyclic or bicyclic heterocyclic ring;
• or Y and Z are linked with R40 such that, together with the nitrogen atom to which they are attached, they form 4 to 10-membered monocyclic or bicyclic heterocyclic ring;
• and wherein any alkylene, alkyl, cycloalkyl or heterocyclyl group present in a R4 substituent group is optionally further substituted by one or more substituent groups independently selected from oxo, halo, nitro, hydroxy, cyano, carboxy, -M-NR41R42, -M-S(O)dR41, -M-C(O)NR41R42, -M-NR41C(O)R42, -M-NR41S(O)2R42, -M-S(O)2NR41R42, (1-5C)alkyl, (1-5C)alkoxy, (1-5C)haloalkyl, (1-5C)haloalkoxy or (1-5C)alkanoyl, and wherein M is absent or (1-4C)alkylene, and R41 and R42 are each independently selected from hydrogen or (1-5C)alkyl;
• or R41 and R42 can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring;
• Q is a group of formula:
• wherein R7 is a group of the formula:
• W2—X2—Y2—X3—Z2
• wherein
• W2 is a linker group of the formula —[CRxRy]r— in which r is 1, Rx is hydrogen and Ry is hydrogen or methyl;
• X2 is absent;
• Y2 is absent;
• X3 is absent;
• and
• Z2 is a 4, 5, 6 or 7-membered nitrogen-linked heterocyclyl optionally comprising one further nitrogen atom;
• and
• wherein Z2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, hydroxy, carboxy, NRddRee, (1-4C)alkoxy, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, (2C)alkanoyl, (1-2C)alkylsulphonyl, C(O)NRddRee, NRddC(O)Ree, NRddSO2Ree and SO2NRddRee;
• wherein Rdd and Ree are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl.